SG11201700089QA - Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria - Google Patents
Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteriaInfo
- Publication number
- SG11201700089QA SG11201700089QA SG11201700089QA SG11201700089QA SG11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA
- Authority
- SG
- Singapore
- Prior art keywords
- formulation
- broad
- vaccine against
- basic units
- multiple epitopes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20141361 | 2014-07-25 | ||
| PCT/EP2015/066988 WO2016012587A1 (en) | 2014-07-25 | 2015-07-24 | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700089QA true SG11201700089QA (en) | 2017-02-27 |
Family
ID=51494387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700089QA SG11201700089QA (en) | 2014-07-25 | 2015-07-24 | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10500263B2 (en) |
| EP (1) | EP3174553B1 (en) |
| CN (1) | CN106659799B (en) |
| CA (1) | CA2954087C (en) |
| DK (1) | DK3174553T3 (en) |
| EA (1) | EA035556B1 (en) |
| ES (1) | ES2672045T3 (en) |
| HU (1) | HUE038212T2 (en) |
| SG (1) | SG11201700089QA (en) |
| WO (1) | WO2016012587A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2672045T3 (en) * | 2014-07-25 | 2018-06-12 | Biosynth S.R.L. | Vaccines of glycoconjugate products comprising basic units of a molecular construction expressing multiple incorporated epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
| US20180169206A1 (en) * | 2015-06-16 | 2018-06-21 | Glaxosmithkline Biologicals, Sa | Immunogenic compositions |
| EP3468530A4 (en) | 2016-06-10 | 2020-03-11 | Clarity Cosmetics Inc. | Non-comedogenic hair and scalp care formulations and method for use |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CN115697396A (en) * | 2020-06-18 | 2023-02-03 | 葛兰素史克生物有限公司 | Shigella-tetravalent (Shigella 4V) bioconjugates |
| WO2022216734A1 (en) * | 2021-04-06 | 2022-10-13 | The Board Of Trustees Of The University Of Illinois | Multivalent cholera multiepitope fusion antigen (mefa) and methods of use |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US203143A (en) * | 1878-04-30 | Improvement in embroidering-machines | ||
| IT1187753B (en) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY |
| US5919463A (en) * | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| US6951652B2 (en) * | 1998-07-29 | 2005-10-04 | Biosynth S.R.L. | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases |
| WO2000061761A2 (en) * | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| AU2002309259A1 (en) | 2002-05-09 | 2003-11-11 | Massimo Porro | Improved polysaccharide and glycoconjugate vaccines_____________ |
| WO2004052394A1 (en) * | 2002-12-06 | 2004-06-24 | Biosynth S.R.L. | Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria |
| EP2172213B1 (en) * | 2003-01-30 | 2013-04-03 | Novartis AG | Injectable vaccines against multiple meningococcal serogroups |
| US7507718B2 (en) | 2005-04-11 | 2009-03-24 | Sanofi Pasteur | Polymyxin B analogs for LPS detoxification |
| JP2009521434A (en) * | 2005-12-22 | 2009-06-04 | サノフィ パストゥール インコーポレイテッド | Derivatized polysaccharide-protein multivalent conjugates and vaccines from Neisseria meningitidis |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| JP5501969B2 (en) * | 2007-09-11 | 2014-05-28 | ユニバーシティ オブ グェルフ | Polysaccharide immunogens derived from Clostridium difficile |
| CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| BR112013027229B1 (en) * | 2011-04-22 | 2020-10-27 | Wyeth Llc | isolated immunogenic polypeptide and its use, immunogenic composition and use, recombinant cell or progeny thereof, and method of producing a mutant clostridium difficile toxin |
| US9815889B2 (en) * | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
| EP2554549A1 (en) * | 2011-08-02 | 2013-02-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Oligosaccharides and oligosaccharides-protein conjugates derived from clostridium difficile polysaccharide PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools |
| JP6203816B2 (en) * | 2012-03-29 | 2017-09-27 | セラバイオーム，エルエルシー | Gastrointestinal site-specific oral vaccination formulation active against ileum and appendix |
| WO2014059296A1 (en) * | 2012-10-12 | 2014-04-17 | Department Of Veterans Affairs | An attenuated ehec and clostridial toxins tcda and tcdb based vaccine for clostridium difficil associated disease (cdad) |
| CN109364244B (en) * | 2012-10-29 | 2022-04-29 | 阿肯色大学评议会 | Mucosal adjuvants and delivery systems |
| CN104756528A (en) * | 2012-11-02 | 2015-07-01 | 瑞典爱立信有限公司 | Methods, a broadcast management unit and a user equipment for handling digital content in a cellular communications network |
| FI3513806T3 (en) * | 2012-12-05 | 2023-04-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| ITMI20130142A1 (en) * | 2013-01-31 | 2014-08-01 | Biosynth Srl | GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED |
| EP3584308A3 (en) * | 2013-02-04 | 2020-03-04 | Seres Therapeutics, Inc. | Compositions and methods |
| PL404229A1 (en) * | 2013-06-06 | 2014-12-08 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Isolated immunogenic bacterial antigen and its use in the prevention and treatment of infections caused by Gram-negative bacteria |
| WO2015100409A2 (en) * | 2013-12-26 | 2015-07-02 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein |
| ES2672045T3 (en) * | 2014-07-25 | 2018-06-12 | Biosynth S.R.L. | Vaccines of glycoconjugate products comprising basic units of a molecular construction expressing multiple incorporated epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
| WO2018067582A2 (en) * | 2016-10-03 | 2018-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv-1 env fusion peptide immunogens and their use |
-
2015
- 2015-07-24 ES ES15742232.0T patent/ES2672045T3/en active Active
- 2015-07-24 US US15/329,205 patent/US10500263B2/en active Active
- 2015-07-24 EP EP15742232.0A patent/EP3174553B1/en active Active
- 2015-07-24 SG SG11201700089QA patent/SG11201700089QA/en unknown
- 2015-07-24 EA EA201692546A patent/EA035556B1/en not_active IP Right Cessation
- 2015-07-24 HU HUE15742232A patent/HUE038212T2/en unknown
- 2015-07-24 DK DK15742232.0T patent/DK3174553T3/en active
- 2015-07-24 CN CN201580039496.6A patent/CN106659799B/en active Active
- 2015-07-24 WO PCT/EP2015/066988 patent/WO2016012587A1/en active Application Filing
- 2015-07-24 CA CA2954087A patent/CA2954087C/en active Active
-
2019
- 2019-10-28 US US16/666,367 patent/US11246919B2/en active Active
-
2021
- 2021-01-25 US US17/157,969 patent/US11576959B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210138059A1 (en) | 2021-05-13 |
| US10500263B2 (en) | 2019-12-10 |
| US11246919B2 (en) | 2022-02-15 |
| CN106659799A (en) | 2017-05-10 |
| ES2672045T3 (en) | 2018-06-12 |
| EA035556B1 (en) | 2020-07-07 |
| CA2954087A1 (en) | 2016-01-28 |
| DK3174553T3 (en) | 2018-07-23 |
| US20200129606A1 (en) | 2020-04-30 |
| EP3174553B1 (en) | 2018-04-18 |
| EP3174553A1 (en) | 2017-06-07 |
| CN106659799B (en) | 2020-07-17 |
| EA201692546A1 (en) | 2017-08-31 |
| US11576959B2 (en) | 2023-02-14 |
| US20170209563A1 (en) | 2017-07-27 |
| CA2954087C (en) | 2023-09-19 |
| WO2016012587A1 (en) | 2016-01-28 |
| HUE038212T2 (en) | 2018-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246978A0 (en) | Novel pharmaceutical formulations | |
| PT3148576T (en) | Vaccine composition against streptococcus suis infection | |
| HK1211224A1 (en) | Multivalent glycoconjugate vaccines | |
| ZA201708713B (en) | Multivalent pneumococcal conjugate vaccine | |
| SG11201700089QA (en) | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria | |
| ZA201604498B (en) | Single vial vaccine formulations | |
| ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
| GB201301085D0 (en) | Glycoconjugate Vaccine | |
| SG11201702298VA (en) | Pharmaceutical preparation | |
| ZA201607355B (en) | Group a streptococcus vaccine | |
| IL248855B (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| HK1258252A1 (en) | Adenine conjugate compounds and their use as vaccine adjuvants | |
| LT3256154T (en) | Pharmaceutical formulation comprising antibody | |
| GB201701400D0 (en) | Compound for use in medicine | |
| PL3200820T3 (en) | Broad-spectrum vaccine against avian reovirus | |
| IL243432A0 (en) | Synthetic oligosaccharides for p. aeruginosa vaccine and uses thereof | |
| EP3166957A4 (en) | Sulfated-glycolipids as adjuvants for vaccines | |
| EP3379974A4 (en) | Supine patient transfer package | |
| GB201616880D0 (en) | Compound for use in medicine | |
| GB201701388D0 (en) | Compound for use in medicine | |
| UA27369S (en) | DISPLAY OF THE PACKAGING FOR "HOME" TEA | |
| UA30852S (en) | DISPLAY OF PACKAGING FOR "ASKOLD" TEA | |
| UA30264S (en) | DRAWING FOR PACKAGING PILLOWS "START!" | |
| UA30262S (en) | DRAWING FOR PACKAGING PILLOWS "START!" |